No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
RDNT240517C55000
- 2.35
- -0.35-12.96%
15min DelayClose May 17 15:59 ET
3.55High1.95Low
3.10Open2.70Pre Close27 Volume248 Open Interest55.00Strike Price7.02KTurnover0.00%IV-0.48%PremiumMay 17, 2024Expiry Date2.45Intrinsic Value100Multiplier0DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type--Delta--Gamma26.41Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- 1D
News
Dhiraj Carumbaya Joins ConcertAI as Senior Vice President and General Manager of TeraRecon
CAMBRIDGE, Mass., May 16, 2024 /PRNewswire/ -- ConcertAI, the leader in oncology predictive and generative AI SaaS Solutions and Real-World Data for healthcare and life sciences, today announced that
Radnet (RDNT) Gets a Buy From Truist Financial
Express News | RadNet Inc : Truist Securities Raises Target Price to $63 From $55
Truist Securities Adjusts Price Target on RadNet to $63 From $55, Maintains Buy Rating
RadNet (RDNT) has an average outperform rating and a price target range of $48 to $61, according to analysts polled by Capital IQ.
RadNet, Inc. to Present at the Bank of America Securities 2024 Health Care Conference on May 14th, 2024
LOS ANGELES, May 13, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient
RadNet, Inc. (NASDAQ:RDNT) Q1 2024 Earnings Call Transcript
Comments
The combination of a rather low ROE and significant use of debt is not particularly appealing. Investors should consider how a company might perform if it was unable to borrow so easily, as credit markets do change over time.
RadNet, Inc. (NASDAQ:RDNT) Delivered A Weaker ROE Than Its Industry 2
RadNet's high P/S ratio may be due to expectations of accelerated revenue performance. However, with revenue growth forecasted to align with the industry, the elevated P/S ratio may not be sustainable. Maintaining the current share price could be challenging unless RadNet outperforms the industry in the short term.
RadNet's CEO sees the Houston acquisition as a strong platform for growth, with potential for more acquisitions, de novo build-outs, health system partnerships, and expansion of AI and digital health solutions. The Houston market aligns with other successful RadNet core geographies.
1
Market focus is on RadNet's top line growth due to its small profit. The share price growth reflects this progress. The recent improvement in total shareholder return could indicate business improvement over time.
RadNet's acquisition is a strategic move to grow its scale and expand patient access in Arizona. The implementation of its digital health solutions is expected to optimize workflow, improve patient experience, and enhance accuracy and early detection.
Read more